EVOK实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (21 May 2024 @ 21:30):

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases...

Stats
今日成交量	3 938.00
平均成交量	30 588.00
市值	4.13M
EPS	$0 ( 2024-05-20 )
下一个收益日期	( $-0.0600 ) 2024-08-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.210
ATR14	$0.00700 (1.49%)

Insider Trading

Date	Person	Action	Amount	type
2023-05-10	Widder Kenneth J	Buy	14 250	Stock Option (Right to Buy)
2023-05-10	Reed Vickie S	Buy	15 000	Stock Option (Right to Buy)
2023-05-10	Hill Malcolm R	Buy	14 625	Stock Option (Right to Buy)
2023-05-10	Garner Cam L	Buy	17 750	Stock Option (Right to Buy)
2023-05-10	Brady Todd C	Buy	14 625	Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 99 transactions
Buy: 6 847 814 \| Sell: 1 253 905

Evoke Pharma Inc 相关性

10 最正相关
AEHR	0.957
VVOS	0.956
INVZ	0.945
EHTH	0.94
WW	0.94
OPEN	0.939
AVXL	0.934
NWFL	0.932
PACB	0.931
VUZI	0.929

10 最负相关
NESR	-0.931
BSCO	-0.916
INBKZ	-0.908
OXSQ	-0.899
ESTA	-0.891
ADTH	-0.889
DXJS	-0.888
APXI	-0.887
KRUS	-0.878
SWAV	-0.877

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Evoke Pharma Inc 财务报表

Annual	2023
营收:	$5.18M
毛利润:	$4.98M (96.10 %)
EPS:	$-2.33

FY	2023
营收:	$5.18M
毛利润:	$4.98M (96.10 %)
EPS:	$-2.33

FY	2022
营收:	$2.51M
毛利润:	$2.14M (85.24 %)
EPS:	$-2.60

FY	2021
营收:	$1.62M
毛利润:	$1.29M (79.72 %)
EPS:	$-3.24

Financial Reports:

No articles found.

Evoke Pharma Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Evoke Pharma Inc

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.